{"status": "Ok", "redirect_url": "https://www.investor.jnj.com/investor-news/news-details/2026/CAPLYTA-lumateperone-showed-greatest-improvement-across-key-efficacy-outcomes-among-adjunctive-MDD-treatments-in-new-network-meta-analysis/default.aspx", "message": "News view counter 699559 successfully enlarged"}